Remap Consulting provides an integrated approach to pharmaceutical pricing & market access solutions.
We are a specialist pricing, reimbursement and market access consultancy offering an integrated, evidence-based approach to optimising market access. Our strength lies in our ability to understand the market access challenges from your perspective and to develop payer-focused solutions tailored to your business needs.
This is a FREE LISTING on PMHUB
Below are full profiles from other companies in related areas
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by strategically aligning promotion, medical education and PR across the product…
Advertising, Branding, Clinical Research, Conference/meetings/events, Creative and design, Digital communications, Management consultancies, Market access, Market research, Marketing consultancies, Medical communications, Medical education, Patient support and adherence, Public relations, Regulatory affairs
MDNT is a native Digital and Omnichannel agency focused solely on the healthcare, pharma, and life science industries. We’re highly experienced, no nonesense, and very good at what we do.
Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national and international reach. As we understand the healthcare market and…
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.
Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make a positive contribution to patient care. Real world experience of…
Company Details
Latest Content from PMHub
Press Releases | December 6, 2019 | Lucid Group Communications Limited
Dec 6, 2019Middlesex House hosted its first Lucid Spirit fundraising activity for its charity partner the Wycombe Homeless Connection. The turnout was excellent, and everyone’s synapses were on fire. However,...
White Papers and Resources | December 5, 2019 | Say Communications
We have a worldwide ‘obesity crisis’. Everyone knows this; obesity is in the news almost every week for one reason or another, but what we seem less sure of is...
White Papers and Resources | December 5, 2019 | OPEN Health
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications
White Papers and Resources | December 5, 2019 | OPEN Health
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’.
White Papers and Resources | December 4, 2019 | Page & Page Health
Personal health and wellbeing has never been more a part of the public conscious than it is now.
White Papers and Resources | December 4, 2019 | Blue Latitude Health
The digital therapeutics market is set to reach almost $1 billion by 2026 as wearables and apps continue to play an important role in enhancing healthcare. However, adoption of these...
Press Releases | November 29, 2019 | Four Agency Worldwide
We’re delighted to have won the Judge’s Special Recognition Award at the PMEA Awards 2019! Huge congratulations to the whole team for another amazing win for the GLAD I Took...
Press Releases | November 27, 2019 | Lucid Group Communications Limited
Lucid Group demonstrates continual investment in its infrastructure by appointing Sebastian Goodwin as its new Legal and Compliance manager.Sebastian studied politics and trained to be a lawyer before moving into...
Press Releases | November 27, 2019 | Lucid Group Communications Limited
This time of year can be busier than normal. Lucid Group understand the importance of taking some time out to relax and unwind. That's why yesterday, relaxation, meditation and mindfulness...
White Papers and Resources | November 27, 2019 | OPEN Health
A recent blog, published by Sarah Tressel Gary and Rinah Yamamoto called “Patient-Reported Outcome Data in Oncology Trials - Part 2: Clinical Benefit and Patient Preference”, has sparked our interest....